Pfizer partners with Enodia Therapeutics in $500m drug deal

Pfizer Inc (PFE) stock rose 3.14% on October 14, outperforming its sector and peers. The increase followed a collaboration announcement with Enodia Therapeutics, upcoming research presentations, and positive earnings revisions. Analysts note technical buy signals but caution about downgrades, COVID-19 revenue declines, and patent expirations. The company's revenue was $62.58B, with a net profit of $7.77B. Analysts' average price target is $29.03.

Pfizer (NYSE: PFE) will present data from over 50 studies at IDWeek 2026, showcasing advancements in infectious disease prevention and treatment. Key highlights include Phase 2 and 3 results for next-generation vaccines, such as a 25-valent pneumococcal vaccine and a Lyme disease vaccine. The company also shares real-world data on the effectiveness of its RSV and pneumococcal vaccines.

Pfizer will present data from nursing homes on its RSV vaccine, ABRYSVO, after three seasons. The company will also share updates on its pneumococcal, COVID-19, and Lyme disease vaccines at IDWeek 2026. Key studies include Phase 3 results for Lyme vaccine LB6V and real-world effectiveness data for ABRYSVO and PREVNAR 20.

Johnson & Johnson (JNJ) stock fell 5% despite raising its full-year outlook due to one-time charges, including talc litigation. Q3 2026 revenue grew 5.9%, but reported net earnings dropped 95.9%. Eli Lilly (LLY) and Pfizer (PFE) also saw declines. JNJ's growth came from its Innovative Medicine division, while MedTech lagged. The company secured market authorization for its OTTAVA robotic surgical system and priority review for RYBREVANT FASPRO.

Enodia Therapeutics and Pfizer Inc. agreed to collaborate on developing Sec61-targeting small molecules. Enodia will handle discovery, while Pfizer will manage clinical, manufacturing, and commercial activities post-collaboration. Enodia may receive over $500 million in upfront, milestone, and royalty payments.

Pfizer presented phase 3 trial results showing Litfulo (ritlecitinib) significantly improved facial and total body repigmentation in nonsegmental vitiligo compared to placebo. The trials, TRANQUILLO 2 and TRANQUILLO, also showed reduced disease severity and stabilization. Pfizer plans to submit the data to global regulators, including the FDA and EMA. According to Pfizer, Litfulo addresses the root cause of the disease.